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Genome-wide association study identifies 30 Loci Associated 
with Bipolar Disorder
A full list of authors and affiliations appears at the end of the article.
Abstract
Bipolar disorder is a highly heritable psychiatric disorder. We performed a genome-wide 
association study including 20,352 cases and 31,358 controls of European descent, with follow-up 
analysis of 822 variants with P<1×10−4 in an additional 9,412 cases and 137,760 controls. Eight of 
the 19 variants that were genome-wide significant (GWS, p < 5×10−8) in the discovery GWAS 
were not GWS in the combined analysis, consistent with small effect sizes and limited power but 
also with genetic heterogeneity. In the combined analysis 30 loci were GWS including 20 novel 
loci. The significant loci contain genes encoding ion channels, neurotransmitter transporters and 
synaptic components. Pathway analysis revealed nine significantly enriched gene-sets including 
regulation of insulin secretion and endocannabinoid signaling. BDI is strongly genetically 
correlated with schizophrenia, driven by psychosis, whereas BDII is more strongly correlated with 
major depressive disorder. These findings address key clinical questions and provide potential new 
biological mechanisms for BD.
Bipolar disorder (BD) is a severe neuropsychiatric disorder characterized by recurrent 
episodes of mania and depression that affect thought, perception, emotion, and social 
behaviour. A lifetime prevalence of 1-2%, elevated morbidity and mortality, onset in young 
adulthood, and a frequently chronic course make BD a major public health problem and a 
leading cause of the global burden of disease 1. Clinical, twin and molecular genetic data all 
strongly suggest that BD is a multifactorial disorder 2. Based on twin studies, the overall 
heritability of BD has been estimated to be more than 70% 3,4, suggesting a substantial 
involvement of genetic factors in the development of the disorder, although non-genetic 
factors also influence risk.
BD can be divided into two main clinical subtypes 5,6: bipolar I disorder (BD1) and bipolar 
II disorder (BD2). In BD1, manic episodes typically alternate with depressive episodes 
during the course of illness. Diagnosis of BD2 is based on the lifetime occurrence of at least 
one depressive and one hypomanic (but no manic) episode. Although modern diagnostic 
systems retain the Kraepelinian dichotomy 7 between BD and schizophrenia (SCZ), the 
distinction between the two disorders is not always clear-cut, and patients who display 
clinical features of both disorders may receive a diagnosis of schizoaffective disorder-bipolar 
type (SAB). Likewise, in genetic studies BD and SCZ are usually treated separately, 
although recent epidemiological and molecular genetic studies provide strong evidence for 
some overlap between the genetic contributions to their etiology 2,8.
Recent genome-wide association studies (GWAS) in BD have identified a number of 
significant associations between disease status and common genetic variants 9–23. The first 
large collaborative BD GWAS by the multinational Psychiatric Genomics Consortium 
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(PGC) Bipolar Disorder Working Group comprised 7,481 BD patients and 9,250 controls 
and identified four genome-wide significant loci 9. Three subsequent meta-analyses that 
included the PGC BD data 10,12,18 identified an additional 5 loci.
Estimates of the proportion of variance in liability attributable to common variants genome-
wide (SNP-heritability) indicate that ~30% of the heritability for BD is due to common 
genetic variants 8. To date, only a small fraction of this heritability is explained by associated 
loci, but results from other human complex traits suggest that many more will be identified 
by increasing the sample size of GWAS 24. Here, we report the second GWAS of the PGC 
Bipolar Disorder Working Group, comprising 20,352 cases and 31,358 controls of European 
descent in a single, systematic analysis, with follow up of top findings in an independent 
sample of 9,412 cases and 137,760 controls. Some of our findings reinforce specific 
hypotheses regarding BD neurobiology; however, the majority of the findings suggest new 
biological insights.
RESULTS
GWAS of bipolar disorder (BD)
We performed a GWAS meta-analysis of 32 cohorts from 14 countries in Europe, North 
America and Australia (Supplementary Table 1A), totaling 20,352 cases and 31,358 controls 
of European descent (effective sample size 46,582). This is a large GWAS of BD, a 2.7-fold 
increase in the number of cases compared to our previous GWAS 9, and includes 6,328 case 
and 7,963 control samples not previously reported. We imputed variant dosages using the 
1,000 Genomes reference panel, retaining association results for 9,372,253 autosomal 
variants with imputation quality score INFO > 0.3 and minor allele frequency ≥ 1% in both 
cases and controls. We performed logistic regression of case status on imputed variant 
dosage using genetic ancestry covariates. The resulting genomic inflation factor (λGC) was 
1.23, 1.01 when scaled to 1,000 cases and 1,000 controls (λ1000) (Supplementary Figure 1). 
The LD Score regression intercept was 1.021 (se=0.010), and the attenuation ratio of 0.053 
(se=0.027) was non-significant, indicating that the observed genomic inflation is indicative 
of polygenicity rather than stratification or cryptic population structure 25. The LD-score 
regression SNP-heritability estimates for BD were 0.17-0.23 on the liability scale assuming 
population prevalence of 0.5-2%. See Supplementary Table 1A, Online Methods and 
Supplementary Note for sample and method details.
We find a marked increase in phenotypic variance explained by genome-wide polygenic risk 
scores (PRS) compared to previous publications (sample size weighted mean observed 
Nagelkerke’s R2 = 0.08 across datasets, liability scale R2=0.04, for p-threshold 0.01; 
Supplementary Figure 2 and Supplementary Table 2). Among the different datasets, we 
observed no association between the PRS R2 and: (i) the gender distribution of the BD cases 
(p=0.51); (ii) the proportion of cases with psychosis (p=0.61); (iii) the proportion with a 
family history of BD (p=0.82); or (iv) the median age of onset for BD (p=0.64). In our 
primary genome-wide analysis, we identified 19 loci exceeding genome-wide significance 
(P< 5×10−8; Table 1).
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Follow-up of suggestive loci in additional samples
We tested lead variants that were significant at P<1×10−4 in our discovery GWAS meta-
analysis, a total of 794 autosomal and 28 X chromosome variants, for association in follow-
up samples totaling 9,412 cases and 137,760 controls of European ancestry (effective sample 
size 23,005; Supplementary Note and Supplementary Table 1B). We first compared 
discovery and follow-up sample summary statistics using LD score regression, and 
estimated their genetic correlation to be 0.98 (se=0.07), consistent with homogeneous 
genetic effects between the two samples. Discovery and follow-up samples also show similar 
patterns of significant genetic correlations with a range of other human diseases and traits in 
the LD Hub database 26 (Supplementary Table 3; correlation of 0.93, p = 8.3×10−14, 
Supplementary Figure 3).
Thirty autosomal loci achieved genome-wide significance (P< 5×10−8) in fixed-effect meta-
analysis of our GWAS and follow-up samples (Figure 1, Table 1A, Supplementary Data 1–3, 
Supplementary Table 4). In Supplementary Table 5, we present detailed descriptions of the 
associated loci and genes, with bioinformatic and literature evidence for their potential roles 
in BD. Of the 30 genome-wide significant loci from our combined analysis, 20 are novel BD 
risk loci. These include 19 loci that were significant only in the combined analysis, of which 
three were reported to have genome-wide significant SNPs in previous studies (ADCY2 18, 
POU3F2 18, ANK3 12,18), and 11 that were significant in our primary GWAS. We refer to 
loci by the gene name attributed in previous BD GWAS publications, or by the name of the 
closest gene for novel loci, without implication that the named gene is causal. Results for all 
variants tested in the follow-up study are presented in Supplementary Table 4.
Of the 19 variants that were genome-wide significant in the discovery GWAS, 8 were not 
genome-wide significant in the combined analysis (Table 1B), and 11 were non-significant 
in one-tailed association tests in the follow-up samples (p>0.05 in Table 1). Still, the follow-
up results for these 19 variants are clearly non-null in aggregate: all 19 had consistent 
directions of effect between discovery GWAS and follow-up (9.5 expected by chance, 
binomial test p=4×10−6), and eight of the 19 had follow-up 1-tailed p<0.05 (1 expected by 
chance, sign test p=2×10−6). Using effect sizes corrected for winner’s curse 27,28 for each of 
the 19 variants that were genome-wide significant in the GWAS, we calculated power to 
achieve significant results (1-tailed p<0.05) in the follow-up samples or genome-wide 
significance in combined analysis (Supplementary Note, Supplementary Table 6, 
Supplementary Figure 4). We found that the number of variants significant in follow-up is 
close to expectation (8 observed with follow-up p<0.05, 8.26 expected, Poisson binomial p = 
0.57), and that 11 variants achieving genome-wide significance in the combined analysis is 
also within the expected range (p = 0.29). As an alternative to winner’s curse correction, we 
conducted a polygenic inference analysis using a mixture of Gaussian effect size 
distributions to model BD genetic architecture and estimate the variants’ true effect sizes 29 
(Supplementary Note, Supplementary Figure 5). Under this model, we found that only two 
variants were nominally significantly weaker in follow-up than expected by chance 
(TRANK1 rs9834970 p = 0.012, and rs13821 p = 0.026; Supplementary Table 7), and none 
were Bonferroni significant (p>0.05/19=0.0026). Thus, the overall replication rate is within 
the expected range given the polygenic architecture of BD.
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We next asked if the variants tested in the follow-up samples were, in aggregate, consistent 
with the presence of additional sub genome-wide significant BD association signals. After 
excluding 47 variants that were genome-wide significant in our GWAS, our combined 
analysis or previous BD GWAS, 775 variants remained in our follow-up experiment. 551 
variants had the same direction of effect in the discovery GWAS and follow-up (71%, 
compared to a null expectation of 50%, sign test p = 1.3×10−32), and 110 variants had the 
same direction of effect and were nominally significant (p<0.05) in the follow-up (14%, 
compared to an expected value of 5%, binomial test p = 2.1×10−22). This consistency 
between our GWAS and follow-up results suggests that many more true BD associations 
exist among these variants.
To identify additional independent signals, we conducted conditional analyses across each of 
the 30 significant BD loci (Supplementary Table 8). We used the effective number of 
independent variants based on LD structure within loci 30 to calculate a multiple test-
corrected significance threshold (p=1.01×10−5, see Supplementary Note). Only one locus 
showed evidence for an independent association signal (rs114534140 in locus #8, FSTL5; 
pconditional = 2×10−6). At another locus (#30,STK4 on chr 20), we found two SNPs with 
genome-wide significance in low LD (R2 < 0.1); however, conditional analysis showed that 
their associations were not independent.
Shared loci and genetic correlations with other traits
We next examined the genetic relationships of BD to other psychiatric disorders and traits. 
Of the 30 genome-wide significant BD loci, 8 also harbor schizophrenia (SCZ) associations 
31,32
. Based on conditional analyses, the BD and SCZ associations appear to be independent 
at 3 of the 8 shared loci (NCAN, TRANK1 and chr7q22.3:105Mb) (Supplementary Table 9). 
No genome-wide significant BD locus overlapped with those identified for depression 
(DEPR), including 44 risk loci identified in the most recent PGC GWAS of major depression 
33
, and those reported in a large study of depressive symptoms or subjective well-being 34. 
As previously reported 35, we found substantial and highly significant genetic correlations 
between BD and SCZ 31 (LD-score regression estimated genetic correlation rg = 0.70, se = 
0.020) and between BD and DEPR 33 (rg = 0.35, se = 0.026). The BD and DEPR genetic 
correlation was similar to that observed for SCZ and DEPR (rg = 0.34, se = 0.025) 
(Supplementary Table 10A).
We found significant genetic correlations between BD and other psychiatric-relevant traits 
(Supplementary Table 10B), including autism spectrum disorder 8 (rg = 0.18, P=2×10−4), 
anorexia nervosa 36 (rg = 0.23, P=9×10−8), and subjective well-being 34 (rg = −0.22, 
P=4×10−7). There was suggestive positive overlap with anxiety disorders (rg=0.21, P=0.04) 
37
 and neuroticism (rg=0.12, P=0.002) 38. Significant rgs were seen with measures of 
education: college attendance 39 (rg = 0.21, P=1=x10−7) and education years 40 (rg=0.20, 
P=6×10−14), but not with childhood IQ 41 (rg=0.05, P=0.5) or intelligence 42 (rg=−0.05, 
P=0.08). Among a large number of variants in BD risk loci that were associated with 
additional traits in the GWAS catalog 43, we found a handful of loci with non-independent 
associations (in one overlapping locus with each of educational attainment, biliary atresia, 
bone mineral density, lipid-related biomarkers) (Supplementary Table 9). Biliary atresia and 
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lipid- related biomarkers, however, did not show significant genetic correlation with BD 
(Supplementary Table 10B).
BD subtypes
We performed a secondary GWAS focusing on three clinically recognized subtypes of 
bipolar disorder: BD1 (n=14,879 cases), BD2 (n=3,421 cases), and SAB (n=977 cases) 
(Supplementary Note, Supplementary Tables 1A & 11, Supplementary Figure 6). We 
observed variants in 14 loci with genome-wide significance for BD1, 10 of which were in 
genome-wide significant loci in the combined BD GWAS analysis. Not surprisingly given 
the sample overlap, 3 of the 4 remaining loci genome-wide significant for BD1 have P < 
10−6 in either our discovery GWAS or combined analysis. The remaining locus (MAD1L1, 
chr7:1.9Mb, discovery GWAS p = 2.4×10−6) was recently published in two BD GWAS that 
included Asian samples 44,45. We did not observe genome-wide significant results for the 
smaller BD2 and SAB analyses. BD1, BD2 and SAB all have significant common variant 
heritabilities (BD1 h2snp = 0.25, se = 0.014, p = 3.2×10−77; BD2 h2snp = 0.11, se = 0.028, p 
= 5.8×10−5; SAB h2snp = 0.25, se = 0.10, p = 0.0071). Genetic correlations among BD 
subtypes show that these represent closely related, yet partially distinct, phenotypes 
(Supplementary Table 12).
We conducted polygenic risk score (PRS) analyses to explore the relationship between 
genetic risk of SCZ and DEPR, and BD subtypes and psychosis (Figure 2, Supplementary 
Table 13). PRS calculated from SCZ 31 were significantly higher in BD1 cases than in BD2 
cases (p=5.6×10−17, P threshold = 0.1) and in cases with psychosis compared to those 
without psychosis (p=2.12×10−6, P threshold =0.1). Conversely, PRS calculated from DEPR 
33
 were significantly higher in BD2 cases than in BD1 cases (P=8.5×10−10, P threshold = 
0.01), independent of psychosis. Genetic correlations from LD-score regression support 
these results; genetic correlations were greater for SCZ with BD1 (rg = 0.71, se = 0.025) 
than with BD2 (rg = 0.51, se = 0.072), and were greater for DEPR with BD2 (rg = 0.69, se = 
0.093) than with BD1 (rg = 0.30, se = 0.028) (Supplementary Table 12).
Systems biology and in silico functional analyses
We tested for functional genomic enrichment in our BD GWAS using partitioned LD-score 
regression and a range of functional annotations across tissues 46 (Supplementary Note, 
Supplementary Table 14). SNP-based BD heritability was most enriched in open chromatin 
annotations in the central nervous system (proportion SNPs = 0.14, proportion h2snp = 0.60, 
enrichment =3.8, p = 3 × 10−14). We also used DEPICT 47 to test for expression of BD-
associated genes across tissues, and found significant enrichment of central nervous system 
(p < 1.4×10−3, FDR < 0.01) and neurosecretory system (p = 2.0×10−6, FDR < 0.01) genes 
(Supplementary Table 15).
To prioritize genes that may play a functional role in BD, we integrated BD GWAS 
association statistics with eQTL (SNP-gene expression association) and mQTL (SNP-DNA 
methylation association) data using summary Mendelian randomization (SMR) 48,49,50 
(Supplementary Table 16; Supplementary Note). SMR identified 21 genes using eQTL data 
that were significant after multiple testing correction, without evidence of heterogeneity 
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between GWAS and eQTL association signals. Association with GNL3 was observed in 
both brain and blood, highlighting the utility of using blood eQTL data as proxy for brain 
eQTLs 50. Methylation profiles at 6 CpGs in brain and 10 CpGs in blood were associated 
with BD, four of which overlapped between brain and blood mQTL: MUSTN1, GLT8D1, 
HAPLN4 and FADS2.
Finally, we used MAGMA 51 to conduct a gene-wise BD GWAS and to test for enrichment 
of pathways curated from multiple sources (see Supplementary Note). We note that 
significance levels were assigned to genes by physical proximity of SNPs, and do not imply 
that significant genes are causal for BD. Genic association results included 154 Bonferroni 
significant genes (MAGMA pJOINT < 2.8×10−6), including 82 genes in 20 genome-wide 
significant loci, and 73 genes in 27 additional loci that did not reach genome-wide 
significance (Supplementary Table 17). Nine related pathways were significantly enriched 
for genes with BD associations (p < 7.0×10−5, FDR < 0.05), including abnormal motor 
coordination/balance pathways (from mice), regulation of insulin secretion, and 
endocannabinoid signaling (Supplementary Table 18, Supplementary Figure 7).
DISCUSSION
We carried out a large bipolar disorder (BD) GWAS and identified 30 genome-wide 
significant loci, including 20 that were novel. Previous BD GWAS have reported a total of 
20 loci significantly associated with BD9–23 ; twelve of these previously reported loci were 
not genome-wide significant in our GWAS meta analysis, but all had PGWAS ≤ 1.3×10−5 
(Supplementary Table 4C). Our recent GWAS of BD and SCZ 52, which included our 
discovery GWAS data jointly analyzed with published SCZ data 31 (without overlapping 
control subjects), highlighted similarities and differences in BD and SCZ in terms of known 
associated SNPs and PRS-subphenotype associations; here we maximized power to identify 
BD associations. Phenotypic variance explained by polygenic risk scores (PRS) based on 
our BD GWAS data is ~8% (observed scale; 4% on the liability scale 53), an increase from 
2.8% (1.2% on the liability scale) in our previous study 9. The results of our BD subtype 
PRS analyses support the nosological distinction between BD1 and BD2, but also highlight 
the importance of psychosis beyond DSM subtypes, corroborating and expanding evidence 
from previous clinical 54 and genetic studies 52,55,56. The DEPR vs. BD PRS analyses 
provide further support for the distinction between BD1 and BD2, independent of the 
presence of psychosis.
Of the 19 loci identified in our discovery GWAS, only 11 were genome-wide significant in 
meta-analysis of our GWAS and follow-up samples. These results are not unexpected given 
small effect sizes, the winner’s curse 28,57 (Supplementary Note and Supplementary Figure 
4); SNPs can teeter-totter around the genome-wide significance threshold even as sample 
sizes increase. Genetic heterogeneity observed among BD GWAS cohorts8 could also 
contribute to inconsistent replication results; we observed variable polygenic effects between 
BD subtypes (Figure 2, Supplementary Table 13) as well as between cohorts in our study 
(Supplementary Figure 2, Supplementary Table 4) which used a diversity of criteria to define 
cases (Supplementary Note). Remarkably, the strongest association signal from the 
discovery GWAS, at the TRANK1 locus (rs9834970; pcombined = 5.7E-12, OR = 0.93), 
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exhibited significant heterogeneity among discovery GWAS cohorts (Cochran’s Q p = 
1.9×10−4), and did not replicate in the follow-up sample (1-tailed pfollowup = 0.3) 
(Supplementary Data 2 & 3). This locus has been significant in recent 11,12,17,18 but not 
earlier BD GWAS 9,13,20. Thus, complex genetic architecture as well as phenotypic 
heterogeneity may contribute to the inconsistency of genome-wide significant findings 
within and across BD GWAS studies. The observed heterogeneity is a major challenge for 
GWAS of psychiatric disorders and calls for careful and systematic clinical assessment of 
cases and controls in parallel with continued efforts to collect larger sample sizes.
Of the 30 BD associated loci, 8 also harbor associations 31,32,58 with schizophrenia (SCZ); 
however, conditional analyses suggest that the BD and SCZ associations at 3 of the 8 shared 
loci (in the NCAN, TRANK1 and chr7q22.3:105 Mb loci) may be independent 
(Supplementary Table 9). Differential BD and SCZ associations may represent opportunities 
to understand the genetic distinctions between these closely related and sometimes clinically 
difficult to distinguish disorders. We did not find BD loci that overlap with those associated 
with major depression33.
The confirmed association within loci containing CACNA1C and other voltage-gated 
calcium channel genes supports the rekindled interest in calcium channel antagonists as 
potential treatments for BD, with similar examination ongoing for other genes implicated in 
SCZ GWAS 59. Other genes within novel BD-associated loci include those coding for other 
ion channels and transporters (SCN2A, SLC4A1), neurotransmitter receptors (GRIN2A) and 
synaptic components (RIMS1, ANK3). Further study will confirm whether or not these are 
the causal genes in the loci. These processes are important in neuronal hyperexcitability60, 
an excess of which has been reported in iPSC derived neurons from BD patients, and which 
has been shown to be affected by the classic mood stabilizing drug lithium 61. In addition, 
SMR eQTL and mQTL analyses implicate GLT8D1, which is involved in proliferation and 
differentiation of neural stem cells 62. Pathway analyses reveal new genetic evidence for 
insulin secretion and endocannabinoid signaling in BD. There is evidence of insulin action 
in the brain 63 and in BD 64. The endocannabinoid system has possible roles in 
schizophrenia 65,66 and depression 67. Top genes appearing in these pathways include 
calcium and potassium channel subunit, MAP kinase and GABA-A receptor subunit genes 
(Supplementary Table 18).
We observe significant positive genetic correlations with educational attainment, but not 
with either adult or childhood IQ, suggesting that the role of BD genetics in educational 
attainment may be independent of general intelligence. This result is inconsistent with 
suggestions from epidemiological studies 68, but in agreement with a recent clinical study 69.
In summary, findings from the genome-wide analysis of BD reveal an extensive polygenic 
genetic architecture of the disease, implicate brain calcium channels and neurotransmitter 
function in BD etiology, and confirm that BD is part of a spectrum of highly correlated 
psychiatric and mood disorders.
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Accession codes:
Accessioned data were part of the following datasets analyzed in this study. Fat2: 
phs000167.v1.p1 or PGC bundle phs001254.v1.p1 (MGS nonGAIN controls). Gain: dbGAP 
phs000017.v3.p1 (GAIN Bip cases/controls), phs000021.v3.p2 (GAIN scz controls); also 
part of the PGC dbGAP bundle phs001254.v1.p1. Jjst: phs000092.v1.p1 or PGC bundle 
phs001254.v1.p1 (SAGE controls). St2c, NIMH RGR Bipolar Study 19 (STEP-BD), dbGAP 
phs000294.v1.p1 (MIGEN controls). Mich: NIMH RGR Bipolar Study 2 (Pritzker). Wtcc: 
EGAD00000000002.
Data Availability.
The PGC’s policy is to make genome-wide summary results public. Summary statistics for 
our meta-analysis are available through the PGC (https://www.med.unc.edu/pgc/results-and-
downloads). Data are accessible with collaborative analysis proposals through the Bipolar 
Disorder working group of the PGC (https://med.unc.edu/pgc).
ONLINE METHODS
GWAS and follow-up cohorts.
Our discovery GWAS sample was comprised of 32 cohorts from 14 countries in Europe, 
North America and Australia (Supplementary Table 1A), totaling 20,352 cases and 31,358 
controls of European descent. A selected set of variants (see below) were tested in 7 follow-
up cohorts of European descent (Supplementary Table 1B), totalling 9,025 cases and 
142,824 controls (Neff = 23,991). The Supplementary Note summarizes the source and 
inclusion/exclusion criteria for cases and controls for each cohort. All cohorts in the initial 
PGC BD paper were included 9. Cases were required to meet international consensus criteria 
(DSM-IV or ICD-10) for a lifetime diagnosis of BD established using structured diagnostic 
instruments from assessments by trained interviewers, clinician-administered checklists, or 
medical record review. In most cohorts, controls were screened for the absence of lifetime 
psychiatric disorders and randomly selected from the population.
GWAS cohort analysis
We tested 20 principal components for association with BD using logistic regression; seven 
were significantly associated with phenotype and used in GWAS association analysis (PCs 
1-6, 19). In each cohort, we performed logistic regression association tests for BD with 
imputed marker dosages including 7 principal components to control for population 
stratification. For all GWAS cohorts, X-chromosome association analyses were conducted 
separately by sex, and then meta-analyzed across sexes. We also conducted BD1, BD2, and 
SAB GWAS, retaining only cohorts with at least 30 subtype cases and filtering SNPs for 
MAF > 0.02. Results were combined across cohorts using an inverse variance-weighted 
fixed effects meta-analysis 70. We used Plink ‘clumping’ 71,72 to identify an LD-pruned set 
of discovery GWAS meta-analysis BD-associated variants (P < 0.0001, and distance >500 
kb or LD r2 < 0.1, n variants =822) for analysis in the follow-up cohorts. Conditional 
analyses were conducted within each GWAS cohort and meta-analyzed as above.
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Follow-up cohort analysis.
In each follow-up cohort we performed BD association analysis of the 822 selected GWAS 
variants (when available) including genetic ancestry covariates, following QC and analysis 
methods of the individual study contributors. We performed inverse variance-weighted 
fixed-effects meta-analyses of the association results from the follow-up cohorts, and of the 
discovery GWAS and follow-up analyses.
Polygenic risk score (PRS) analyses.
We tested PRS for our primary GWAS on each GWAS cohort as a target set, using a GWAS 
where the target cohort was left out of the meta-analysis (Supplementary Table 2). To test 
genetic overlaps with other psychiatric diseases, we calculated PRS for DEPR and SCZ in 
our GWAS cohort BD cases 73. In pairwise case subtype or psychosis analyses (Figure 2, 
Supplementary Table 13), we regressed outcome on the PRS adjusting for ancestry principal 
components and a cohort indicator using logistic regression, and visualized covariate-
adjusted PRS in BD1 and BD2 subtypes (Figure 2). Outcome sample sizes were BD1 
n=8,044, BD2 n=3,365, SAB n=977; BD1 cases with and without psychosis n= 2175 and 
798 respectively, BD2 cases with and without psychosis n= 146 and 660.
Linkage disequilibrium (LD) score regression.
LD score regression 25,26 was used to conduct SNP-heritability analyses from GWAS 
summary statistics. LD score regression bivariate genetic correlations attributable to 
genome-wide common variants were estimated between the full BD GWAS, BD subtype 
GWASs, and other traits and disorders in LD-Hub 26. We also used LD score regression to 
partition heritability by genomic features 46.
Relation of BD GWA findings to tissue and cellular gene expression.
We used partitioned LD score 47,74 and DEPICT 47 regression to evaluate which somatic 
tissues and brain tissues were enriched in the BD GWAS. We used summary-data-based 
Mendelian randomization (SMR) 48,50 to identify SNPs with strong evidence of causality of 
brain or blood gene expression or methylation in BD risk (Supplementary Table 16), with a 
test for heterogeneity to exclude regions with LD between distinct causal SNPs (pHET < 
0.01).
Gene-wise and pathway analysis.
Guided by rigorous method comparisons conducted by PGC members 51,75, p-values 
quantifying the degree of association of genes and gene sets with BD were generated using 
MAGMA (v1.06) 51. We used ENSEMBL gene coordinates for 18,172 genes giving a 
Bonferroni corrected P-value threshold of 2.8×10−6. Joint multi-SNP LD-adjusted gene-
level p-values were calculated using SNPs 35 kb upstream to 10 kb downstream, adjusting 
for LD using 1,000 Genomes Project (Phase 3 v5a, MAF ≥ 0.01, European-ancestry 
subjects) 76. Gene sets were compiled from multiple sources. Competitive gene set tests 
were conducted correcting for gene size, variant density, and LD within and between genes. 
The pathway map (Supplementary Figure 5) was constructed using the kernel generative 
topographic mapping algorithm (k-GTM) as described by 77.
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Genome build.
All genomic coordinates are given in NCBI Build 37/UCSC hg19.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Editorial Summary:
Genome-wide analysis identifies 30 loci associated with bipolar disorder, allowing for 
comparisons of shared genes and pathways with other psychiatric disorders, including 
schizophrenia and depression.
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Figure 1. 
Manhattan plot for our primary genomewide association analysis of 20,352 cases and 31,358 
controls. GWAS -log10P-values are plotted for all SNPs across chromosomes 1-22 
(diamonds, green for loci with lead SNP GWAS P < 10−6). Combined GWAS+followup 
−log10P-values for lead SNPs reaching genome-wide significance in either GWAS or 
combined analysis (triangles, inverted if GWAS+followup −log10P > GWAS -log10P). 
Labels correspond to gene symbols previously reported for published loci (black) and the 
nearest genes for novel loci (blue), at top if GWAS+followup P < 5×10−8. Loci with one-
tailed follow-up p > 0.05 (Table 1) have dotted underlined locus names.
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Figure 2. 
Association of BD1 and BD2 subtypes with schizophrenia (SCZ) and major depression 
(DEPR) polygenic risk scores (PRS). Shown are mean PRS values (1 s.e. error bars), 
adjusted for study and ancestry covariates and scaled to the PRS mean and sd in control 
subjects, in BD1 (red) and BD2 (blue) cases, for increasing source GWAS P-value 
thresholds (increasing grey) as indicated. P-values (italics) test BD1 vs BD2 mean PRS, in 
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logistic regression of case subtype on PRS with covariates. Results are detailed in 
Supplementary Table 13.
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